Hologic, Inc. (NASDAQ:HOLX) Given Consensus Rating of "Hold" by Brokerages

Shares of Hologic, Inc. (NASDAQ:HOLX - Get Free Report) have earned an average rating of "Hold" from the seventeen analysts that are presently covering the company, Marketbeat Ratings reports. Ten analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $85.77.

Several research firms have issued reports on HOLX. Royal Bank of Canada cut their price objective on Hologic from $88.00 to $85.00 and set a "sector perform" rating on the stock in a report on Thursday, February 6th. Raymond James reaffirmed an "outperform" rating and set a $90.00 target price (down previously from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Leerink Partners cut Hologic from an "outperform" rating to a "market perform" rating and lowered their target price for the company from $80.00 to $75.00 in a research note on Thursday, February 6th. Jefferies Financial Group started coverage on Hologic in a research note on Tuesday, December 10th. They set a "hold" rating and a $85.00 target price on the stock. Finally, StockNews.com raised Hologic from a "hold" rating to a "buy" rating in a research note on Thursday, November 14th.

Hologic Price Performance

Hologic stock traded up $0.09 during midday trading on Monday, hitting $63.62. The company's stock had a trading volume of 1,940,048 shares, compared to its average volume of 2,545,433. The stock's 50-day moving average price is $71.28 and its 200-day moving average price is $77.37. The company has a quick ratio of 3.03, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $14.36 billion, a PE ratio of 20.07, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. Hologic has a 12 month low of $63.39 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Analysts anticipate that Hologic will post 4.27 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, COO Essex D. Mitchell sold 24,856 shares of the business's stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.88% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Wolff Wiese Magana LLC bought a new stake in shares of Hologic during the third quarter worth $25,000. General Partner Inc. bought a new stake in shares of Hologic during the fourth quarter worth $26,000. Venturi Wealth Management LLC grew its holdings in shares of Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after purchasing an additional 261 shares during the last quarter. First Horizon Advisors Inc. grew its holdings in shares of Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock worth $39,000 after purchasing an additional 134 shares during the last quarter. Finally, Cromwell Holdings LLC grew its holdings in shares of Hologic by 330.2% during the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider's stock worth $44,000 after purchasing an additional 416 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.